Pfizer Inc $30.47

up +0.22


21/4/2014 11:09 AM  |  NYSE : PFE  
Industries : Drugs / Drug Manufacturers - Major
Get Trend Analysis Icon Get PFE Trend Analysis - it has underperformed the S&P 500 by 22%

Partner Headlines

  1. Benzinga's Volume Movers

    Benzinga
  2. Mid-Morning Market Update: Markets Rise; Halliburton Posts Q1 Profit

    Benzinga
  3. Morning Market Movers

    Benzinga
  4. Rumor: Pfizer Planning $100 Billion Bid For AstraZeneca

    Benzinga
  5. Benzinga's Top #PreMarket Gainers

    Benzinga
  6. Stock Futures Drift Higher After Best Week since July

    FoxBusiness
  7. Wall Street Edges Higher in Quiet Trading

    FoxBusiness
  8. Benzinga's Weekend M&A Chatter

    Benzinga
  9. Sunday Times Reports Pfizer Considering $100B Offer for AstraZeneca

    Benzinga
  10. Time to Sell the Rebound?

    FoxBusiness
  11. Has A Streamlined FDA Raised The Value Of Drug Stocks?

    IBD
  12. Pharmaceutical Stocks For Income, Value, And Growth Investors

    Benzinga
  13. Tax Dodging Companies Cost You More Than $1,200 Each Year

    Benzinga
  14. Market Wrap For April 14: Markets Surge on Positive Retail Data, Citi Earnings

    Benzinga
  15. Two Things You Must Know About Pfizer

    GuruFocus
  16. Top 40 Upcoming Earnings Releases

    Benzinga
  17. Investors: Brace for a Turbulent Second Quarter

    FoxBusiness
  18. US Stock Futures Edge Lower Ahead Of Jobless Claims Data

    Benzinga
  19. Acura Pharmaceuticals Announces Return of Product Rights from Pfizer

    Benzinga
  20. Podcast Patent Battle Roils Big And Small Media

    IBD
  21. Biotechs Struggling To Find A Bottom

    Benzinga
  22. Pfizer falls on cancer drug trial

    IBD
  23. Market Wrap For April 7: Bears In Complete Control As Markets Get Hammered ...

    Benzinga
  24. Pfizer Breast-Cancer Drug Scores, But Street Cautious

    IBD
  25. Morning Market Losers

    Benzinga
  26. Biotech Auxilium Boosts Position In Men's Health Care

    IBD
  27. Despite S&P 500's New High, Stocks Face Challenges

    Benzinga
  28. Amgen Stock Gets Bump Up On Cholesterol Drug Data

    IBD
  29. New Cholesterol Fighters To Take Center Stage At ACC

    IBD
  30. UPDATE: Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results ...

    Benzinga
  31. Depomed A 'Turtle' Gaining In Specialty Pharma Race

    IBD
  32. Five Star Stock Watch: Pfizer

    Benzinga
  33. Which Pharmas Can Keep Up Dividend-Buybacks?

    YCharts
  34. MannKind Corporation: Will It Make It to the Promised Land?

    GuruFocus
  35. Amgen's PCSK9 Scores Against Genetic High Cholesterol

    IBD
  36. Horizon Pharma Banks On Two-For-One Arthritis Drugs

    IBD
  37. UPDATE: Morgan Stanley Reiterates on Pfizer as Vaccine Pipeline is Under-Appreciated

    Benzinga
  38. Stocks Down 1% In Late Afternoon As Volume Picks Up

    IBD
  39. Pfizer's Blockbuster Drug Celebrex To Lose Patent Protection

    Benzinga
  40. Pfizer's

    IBD
  41. Pfizer Loses Patent On Celebrex, Plans To Appeal

    IBD
  42. Pfizer Loses Bid to Hold Celebrex Exclusivity to '15

    FoxBusiness
  43. Pfizer Breast-Cancer Drug To Show If It's For Real

    IBD
  44. Weekly 52-Week Highs Highlight: PFE, DOV, VMW, OMC, KEP

    GuruFocus
  45. Top Owned Health Care Stocks of the Fourth Quarter

    GuruFocus
  46. This Fund Closed in a Positive Terrain as Boeing Continued Its Uptrend

    GuruFocus
  47. Regeneron Cholesterol-Drug Worries Ding Stock

    IBD
  48. Top Three Holdings of a Top Investment Advisory Firm

    GuruFocus
  49. Market Wrap For March 3: Markets Lower On Ukraine Tension

    Benzinga
  50. Auxilium guidance cautious

    IBD
Trading Center